Clinical trial results don’t usually get standing ovations—but Brian Wolpin and his team truly deserved their reception at #ASCO26. Seeing Phase 3 data on the impact of daraxonrasib in patients with advanced pancreatic cancer sent chills through the entire room. 🧵
www.theguardian.com/society/2026...
In partnership with @lustgarten.org & @theaacr.bsky.social, we are funding Wolpin’s work using daraxonrasib for early detection & interception of pancreatic cancer—because the ultimate goal isn’t just extending life; it’s restoring cancer-free futures.
themarkfoundation.org/portfolio/de...
Very happy to present my work at #EACR2026, made possible through the support of EACR- @themarkfdn.bsky.social Postdoctoral Fellowship 😊
#womeninSTEM
The hope & joy from every oncologist & researcher in the room was palpable, and the results are a historic triumph for a disease that has resisted countless targeted therapies. But while this breakthrough is a victory for late-stage patients, we need to keep looking ahead.
The success of daraxonrasib comes through decades of dogged research to unlock a target that had been deemed “undruggable.” Now, we’re building on that momentum to help more patients sooner.
Curious about how this new type of experimental drug works? Check out this fun explainer video from
@stanforddeptmed.bsky.social: www.youtube.com/shorts/Rwzcb...
Julie Marie Mazet delivers the EACR - @themarkfdn.bsky.social Postdoctoral Fellowship Award Lecture on unlocking CD8+ T cell anti-tumour activity in brain metastasis at #EACR2026
Great feature on Drug Discovery Award winner @corsello.bsky.social by @stanforddeptmed.bsky.social!
Corsello and his collaborator, Nathanael Gray, are developing novel molecular glue degraders for #pancreaticcancer.
medicine.stanford.edu/news/stories...
It was a pleasure to present my research at #EACR2026, supported by @helloeacr.bsky.social @themarkfdn.bsky.social postdoctoral fellowship. Thank you to all organizers & participants!